Benjamin F. Edwards & Company Inc. Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

Benjamin F. Edwards & Company Inc. lowered its position in Johnson & Johnson (NYSE:JNJGet Rating) by 0.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 104,466 shares of the company’s stock after selling 84 shares during the period. Johnson & Johnson comprises about 0.8% of Benjamin F. Edwards & Company Inc.’s portfolio, making the stock its 19th largest position. Benjamin F. Edwards & Company Inc.’s holdings in Johnson & Johnson were worth $18,515,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Family CFO Inc purchased a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. Steward Financial Group LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $34,000. Joseph P. Lucia & Associates LLC purchased a new stake in Johnson & Johnson during the first quarter worth about $38,000. Advocacy Wealth Management Services LLC increased its holdings in Johnson & Johnson by 41.4% during the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after buying an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $49,000. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $174.59 on Thursday. The firm has a 50 day moving average of $175.57 and a 200-day moving average of $174.49. The company has a current ratio of 1.42, a quick ratio of 1.14 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a market capitalization of $459.42 billion, a P/E ratio of 25.41, a price-to-earnings-growth ratio of 3.31 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the previous year, the company earned $2.48 EPS. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Insider Activity at Johnson & Johnson

In related news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on JNJ shares. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Raymond James lifted their target price on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. UBS Group reduced their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.